A US Food and Drug Administration (FDA) advisory panel has voted overwhelmingly against a new drug application (NDA) for intranasal carbetocin (Levo Therapeutics Inc.), intended to treat symptoms associated with Prader-Willi Syndrome (PWS). In a 12 to 1 vote on…
Read More